Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+1.0%
$0.01
$0.01
$0.02
$1.15M-1.01453,874 shs347,999 shs
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
$6.70
-20.0%
$0.82
$1.69
$14.81
$16.36MN/A102,599 shs7,639 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.61
-1.3%
$0.58
$0.36
$2.47
$3.55M0.43131,636 shs7,696 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-3.00%+7.78%-3.00%-10.19%
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
0.00%+6,960.06%+6,960.06%+5,360.47%+1,392.20%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.00%-5.21%+3.39%-5.85%-73.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.6534 of 5 stars
0.03.00.04.80.60.00.0
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
1.9073 of 5 stars
3.50.00.00.00.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
0.00
N/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
3.00
Buy$0.8539.32% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$9.78M0.36N/AN/A$4.25 per share0.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/A0.00N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.15
0.91

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
312.44 millionN/ANot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
305.82 million4.88 millionNot Optionable

Recent News About These Companies

NovaBay Pharmaceuticals approves liquidation plan
NovaBay Pharmaceuticals Inc NBY
NovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick Facts
NOVABAY PHARMAC. DL-,01 (B9P0.MU)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0097 +0.00 (+1.04%)
As of 06/18/2025 03:47 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Hemispherx BioPharma stock logo

Hemispherx BioPharma NYSEAMERICAN:HEB

$6.70 -1.68 (-20.05%)
As of 06/13/2025

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

NovaBay Pharmaceuticals stock logo

NovaBay Pharmaceuticals NYSE:NBY

$0.61 -0.01 (-1.31%)
As of 06/18/2025 03:22 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.